Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
hTLR8
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "hTLR8" in MCE Product Catalog:
Target:
Research Areas:
TLR8 agonist 5 is a potent TLR8 agonist with an EC50 value of 20 nM for HEK-Blue hTLR8. TLR8 agonist 5 activates the immune response .
Cat. No.: HY-153460
CAS No.: 2920729-91-3
Target:
Research Areas:
TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis .
Target:
Research Areas:
D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC50 = 24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 (HY-144497). D18 has strong immune activation and anti-tumor activity. D18 commonly used in cancer research, such as colon cancer .
Cat. No.: HY-178037
CAS No.: 3105410-45-2
Research Areas:
TLR9 antagonist 1 is a selective hTLR9 antagonist with an IC50 of 0.1 nM against hTLR9. TLR9 antagonist 1 exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 can be used in the research of systemic lupus erythematosus .
Cat. No.: HY-159178
CAS No.: 1258457-58-7
Target:
Research Areas:
m-AM-BBIQ (compound 10) is a dual TLR7 and TLR8 agonist, with EC50 values of 0.12 μM and 1.7 μM for hTLR7 and hTLR8, respectively .
Target:
Research Areas:
TLR7/8 agonist 8 (compound 24m) is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC50s of 27 and 12 nM for hTLR7 and hTLR8, respectively. TLR7/8 agonist 8 can improve the antitumor activity of PD-1/PD-L1 blockade .
Cat. No.: HY-177300
CAS No.: 1402802-45-2
Research Areas:
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
Cat. No.: HY-170770
CAS No.: 3080931-00-3
Target:
Research Areas:
TLR7/8 agonist 12 (compound 9) is an hTLR7/8 agonist, with EC50 values of 11 nM (hTLR7) and 150 nM (hTLR8), respectively. TLR7/8 agonist 12 has the potential for immunomodulation .
Cat. No.: HY-162845
Target:
Research Areas:
TLR7/8 agonist 11 (compound 30) is a potent agonist of hTLR7 and hTLR8, with EC50s of 31.1 nM and 13.1 nM, respectively. TLR7/8 agonist 11 plays an important role in adaptive and innate immune responses .
Cat. No.: HY-188010
CAS No.: 1449680-12-9
Target:
Research Areas:
TLR8 agonist 11 is a selective human Toll-like receptor 8 (TLR8) agonist. TLR8 agonist 11 activates the hTLR8-dependent NF-κB signaling pathway. TLR8 agonist 11 can be used for the research of inflammation and immune-related diseases .
Cat. No.: HY-175782
Target:
Research Areas:
SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis .
Cat. No.: HY-RS14596
Target:
Research Areas:
TLR8 Human Pre-designed siRNA Set A contains three designed siRNAs for TLR8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-183276
Target:
Research Areas:
TLR8 antagonist-2 (Compound 35) is a selective TLR8 antagonist with an IC50 of 0.032 μM against hTLR8. TLR8 antagonist-2 potently inhibits TLR8-dependent NF-κB activity in cells stimulated with TL8-506 (HY-20457). TLR8 antagonist-2 can be used in research related to inflammatory and immune diseases .
Cat. No.: HY-187531
CAS No.: 2403782-38-5
Research Areas:
TLR7/8/9 antagonist-3 is an orally active antagonist of TLR7, TLR8 and TLR9, with human IC50 values of 0.008 μM, 0.006 μM and 0.072 μM, respectively. TLR7/8/9 antagonist-3 blocks agonist-induced activation of hTLR7, hTLR8, hTLR9, mTLR7 and mTLR9, and reduces serum IFNα and TNFα levels. TLR7/8/9 antagonist-3 can be used in the research of autoimmune diseases .
Cat. No.: HY-P72270
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TLR8; Toll-Like Receptor 8 Transcript Variant 4; Toll Like Receptor 8; CD288 Antigen; Toll-Like Receptor 8; IMD98; CD288; TLR-8; hTLR8
Species:
Source:
Cat. No.: HY-181841
CAS No.: 2796210-93-8
Target:
Research Areas:
TLR8 agonist 10 is a selective TLR8 agonist with an EC50 of 0.019 μM in humans. TLR8 agonist 10 activates TLR8-mediated signaling pathways. As a latency-reversing agent, TLR8 agonist 10 reactivates latent HIV-1 reservoirs. TLR8 agonist 10 activates innate cytotoxic natural killer cells to target HIV-infected CD4 + T cells. TLR8 agonist 10 is applicable to research related to HIV-1 infection .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
